Resolutions at the extraordinary general meeting of Nuevolution AB (publ)

At the extraordinary general meeting of Nuevolution AB (publ) on 11 December 2017, the following resolutions were resolved.                                    

Number of board members

It was resolved that the number of board members, as appointed by the general meeting, should be six with no deputies.

Remuneration to the board members

It was resolved that remuneration to the board of directors on a full year basis shall be paid in a total amount of SEK 1,520,000, which entails an increase on a full year basis of SEK 200,000 for the additional member of the board of directors. It was resolved that the remuneration shall be adjusted in respect of the change of financial year which was resolved by the annual general meeting held on 12 October 2017 and, with regard to the additional member of the board, that was elected by the extraordinary general meeting.

Election of new member of the board of directors

It was resolved, in accordance with the nomination committee’s proposal, to elect Fredrik Arp as new member of the board of directors for the time until the end of the next annual general meeting. It was noted that the board of directors for the time until the end of the next annual general meeting consists of Stig Løkke Pedersen (chairman), Søren Lemonius, Lars Henriksson, Professor Dr. Jutta Monica Heim, Jeanette Wood and Fredrik Arp.

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 7020 0987

Email: ahg@nuevolution.com 

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com 

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information was released for publication at 16:00 CET on 11 December 2017.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.                       

Tags:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas

Subscribe

Documents & Links